American Association of Individual Investors

Why Cassava Sciences, Inc.’s (SAVA) Stock Is Down 17.37%

As of Friday, December 19, Cassava Sciences, Inc.’s SAVA share price has dipped by 17.37%, which has investors questioning if this is right time to buy.
TipRanks on MSN

Sight Sciences price target raised to $12 from $7 at UBS

UBS raised the firm’s price target on Sight Sciences (SGHT) to $12 from $7 and keeps a Buy rating on the shares. Medicare Administrative ...
Nasdaq

Exact Sciences price target raised to $70 from $60 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
Fintel on MSN

Wave Life Sciences (WVE) price target increased by 60.82% to 32.70

The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $32.70 / share. This is an increase of 60.82% from the prior estimate of $20.34 dated December 3, 2025. The ...
Business Insider

Exact Sciences price target lowered to $65 from $82 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...
Yahoo Finance

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...